Three Actors of Entrepreneur Mentoring and Their Impact on Perceived Mentoring Effectiveness: The Korean Formal Mentoring Context

Boyoung Kim(Boyoung Kim) People&Global Business Association 2023 Global Business and Finance Review Vol.28 No.1

Purpose: This study investigates the impact of three actors that influence entrepreneur mentoring—mentor, mentee, and operating agency—on mentoring effectiveness within the context of formal mentoring in Korea. Specifically, the study considers the characteristics of the mentee, mentoring functions provided by the mentor, and support from the operating agency as antecedents to explain the perceived mentoring effectiveness of the mentee. Design/methodology/approach: I conducted two studies. Study 1 involves data from mentees participating in the entrepreneur mentoring program hosted by the Korea Venture Business Association from March to June 2018. Data for Study 2 was collected from mentees participating in the mentoring program hosted by incubating center of university located in South Korea from November to October 2022. Hierarchical regression analysis was used to examine the hypotheses. Findings: First, Study 1 shows that willingness to receive mentoring positively affects entrepreneurial competence improvement, but this impact was insignificant in Study 2. Second, the problem-solving function provided by the mentor presents a significant positive effect on both mentoring satisfaction and entrepreneurial competence improvement. Third, the motivating function undertaken by a mentor only has a significant positive effect on improving entrepreneurial competence in Study 1. This motivating function positively affects mentoring satisfaction and entrepreneur competence improvement in Study 2. Fourth, support from the operating agency has a significant positive impact on both mentoring satisfaction and improving entrepreneurial competence after controlling for the mentor and mentee effects. Research limitations/implications: This study provides a theoretical contribution to the research on entrepreneur mentoring. In this regard, it suggests three actors-based models of mentoring effectiveness and practical implications for organizations executing entrepreneurship mentoring programs. Accordingly, it confirms that the operating agency’s managerial role is necessary for enhancing entrepreneur mentoring effectiveness. Originality/value: Entrepreneur mentoring is implemented via formal mentoring in many developing countries. However, little attention has been paid to the operating agency as the primary determinant affecting mentoring effectiveness. The current study addresses this gap by examining the effects of three actors in formal mentoring— mentee, mentor, and operating agency—on the mentee’s perceived mentoring effectiveness.

[PF-0002] A new NLR mediates RipY recognition from Ralstonia solanacearum phylotype I in Nicotiana benthamiana

Boyoung Kim(Boyoung Kim),Hyein Yu(Hyein Yu),Cécile Segonzac(Cécile Segonzac ) 한국육종학회 2022 한국육종학회 공동학술발표집 Vol.2022 No.-

표준기상년 국가참조표준 활용을 위한 웹기반 데이터베이스 및 시스템 구축

김보영(Boyoung Kim),김현구(Hyun-Goo Kim),윤창열(Chang-Yeol Yun),김신영(Shin Young Kim),김창기(Chang Ki Kim),김진영(Jin-Young Kim),강용혁(Yong-Heack Kang) 한국태양에너지학회 2019 한국태양에너지학회 학술대회논문집 Vol.2019 No.4

신재생에너지 발전량 분석을 위한 표준기상년 지점 선택 방법

김보영(Boyoung Kim),김신영(Shin Young Kim),김창기(Chang-Ki Kim),윤창열(Chang-Yeol Yun),김진영(Jin-Young Kim),강용혁(Yong-Heack Kang),김현구(Hyun-Goo Kim) 한국신재생에너지학회 2019 한국신재생에너지학회 학술대회논문집 Vol.2019 No.5

Uncertainty Evaluation for Model Based Solar Irradiation in Korean Peninsula

Boyoung Kim,Chang Ki Kim,Yong-Heack Kang,Hyun-Goo Kim 한국신재생에너지학회 2019 AFORE Vol.2019 No.11

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Kim, Hyunmee,Kim, Hyeongsoo,Cho, Seong-Kyung,Kim, Jin-Bae,Joung, Boyoung,Kim, Changsoo The Korean Society of Cardiology 2019 Korean Circulation Journal Vol.49 No.3

<P><B>Background and Objectives</B></P><P>Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial hemorrhage (ICH). We assessed the cost-effectiveness of rivaroxaban compared to adjusted-dose warfarin for the prevention of stroke in patients with nonvalvular AF.</P><P><B>Methods</B></P><P>We built a Markov model using the Korean Health Insurance Review & Assessment Service database. The base-case analysis assumed a cohort of patients with prevalent AF who were aged 18 years or older without contraindications to anticoagulation.</P><P><B>Results</B></P><P>Number of patients with CHA<SUB>2</SUB>DS<SUB>2</SUB>-VASc scores 0, 1 and ≥2 were 56 (0.2%), 1,944 (6.3%) and 28,650 (93.5%), respectively. In patients with CHA<SUB>2</SUB>DS<SUB>2</SUB>-VASc scores ≥2, the incidence rate of ischemic stroke was 3.11% and 3.76% in warfarin and rivaroxaban groups, respectively. The incidence rates of ICH were 0.42% and 0.15%, and those of gastrointestinal bleeding were 0.32% and 0.15% in warfarin and rivaroxaban, respectively. Patients with AF treated with rivaroxaban lived an average of 11.8 quality-adjusted life years (QALYs) at a lifetime treatment cost of $20,886. Those receiving warfarin lived an average of 11.4 QALYs and incurred costs of $17,151. Patients with rivaroxaban gained an additional 0.4 QALYs over a lifetime with an additional cost of $3,735, resulting in an incremental cost-effectiveness ratio of $9,707 per QALY.</P><P><B>Conclusions</B></P><P>Patients who had been treated with rivaroxaban may be a cost-effective alternative to warfarin for stroke prevention in Korean patients with AF.</P>

Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis

Kim, In-Soo,Kim, Hyun-Jung,Yu, Hee Tae,Kim, Tae-Hoon,Uhm, Jae-Sun,Kim, Jong-Youn,Joung, Boyoung,Lee, Moon-Hyoung,Pak, Hui-Nam Elsevier 2019 Journal of cardiology Vol.73 No.6

<P><B>Abstract</B></P> <P><B>Background</B></P> <P>Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients. We studied efficacy and safety of NOACs in AF patients receiving amiodarone, P-glycoprotein inhibitor, or polypharmacy.</P> <P><B>Methods</B></P> <P>After a systematic database search (Medline, EMBASE, CENTRAL, SCOPUS, and Web of Science), four phase-III randomized trials comparing NOACs and warfarin in “with/without amiodarone,” “with/without P-glycoprotein inhibitors,” or “with/without multiple (≥5, polypharmacy) concomitant drugs” subgroups were included. The outcomes were pooled using a random-effects model to determine the relative risks (RRs) for stroke/systemic thromboembolism (SSTE), major bleeding (MB), intracranial hemorrhage (ICH), and all-cause mortality.</P> <P><B>Results</B></P> <P>Among patients taking amiodarone, superiority of NOACs over warfarin in non-amiodarone users disappeared in terms of SSTE (<I>p</I> =0.11), MB (<I>p</I> =0.95), ICH (<I>p</I> =0.26), and mortality (<I>p</I> =0.32). No safety benefit (MB) of NOACs compared to warfarin was shown in patients taking P-glycoprotein inhibitors (<I>p</I> =0.47), but SSTE prevention was still superior with NOACs compared to warfarin in the same patient group [RR=0.78 (0.61–0.99), <I>p</I> =0.04, I<SUP>2</SUP> =11%]. In AF patients with polypharmacy, NOACs showed a lower risk of SSTE [RR=0.82 (0.71–0.96), <I>p</I> =0.01, <I>I</I> <SUP>2</SUP> =0%] and mortality [RR=0.91 (0.83–0.99), <I>p</I> =0.04, <I>I</I> <SUP>2</SUP> =0%], but not MB (<I>p</I> =0.81) compared to warfarin.</P> <P><B>Conclusions</B></P> <P>NOACs were equivalent to warfarin among AF patients with concomitant amiodarone use in terms of efficacy, safety, and mortality. There was no safety benefit of NOACs over warfarin in patients using polypharmacy or P-glycoprotein inhibitors.</P> <P><B>Systematic review registration</B></P> <P>The protocol of this meta-analysis was registered on PROSPERO under CRD42018104808 (https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42018104808).</P> <P><B>Highlights</B></P> <P> <UL> <LI> In atrial fibrillation (AF) patients with amiodarone, non-vitamin K antagonist oral anticoagulants (NOACs) showed no benefits compared to warfarin. </LI> <LI> In AF patients with P-glycoprotein inhibitor (P-gp inhibitors), NOAC showed no safety benefits over warfarin. </LI> <LI> NOAC is more effective over warfarin in AF patients with P-gp inhibitor. </LI> <LI> In AF patients with polypharmacy, NOAC showed no safety benefits over warfarin. </LI> <LI> NOAC is more effective over warfarin in AF patients with polypharmacy. </LI> </UL> </P>

Ideal Blood Pressure in Patients With Atrial Fibrillation

Kim, Daehoon,Yang, Pil-Sung,Kim, Tae-Hoon,Jang, Eunsun,Shin, Hyejung,Kim, Ha Yan,Yu, Hee Tae,Uhm, Jae-Sun,Kim, Jong-Youn,Pak, Hui-Nam,Lee, Moon-Hyoung,Joung, Boyoung,Lip, Gregory Y.H. Elsevier 2018 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY - Vol.72 No.11

<P><B>Abstract</B></P> <P><B>Background</B></P> <P>The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for High Blood Pressure in Adults redefined hypertension as systolic blood pressure (BP) ≥130 mm Hg or diastolic BP ≥80 mm Hg. The optimal BP for patients with atrial fibrillation (AF) is uncertain.</P> <P><B>Objectives</B></P> <P>The goal of this study was to investigate the impacts of the 2017 ACC/AHA guideline and to determine the ideal BP threshold for the management of high BP in patients with AF.</P> <P><B>Methods</B></P> <P>This study analyzed data for 298,374 Korean adults with oral anticoagulant–naive, nonvalvular AF obtained from the National Health Insurance Service database from 2005 to 2015.</P> <P><B>Results</B></P> <P>According to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure guideline, 62.2% of the individuals in our sample had hypertension. After applying the 2017 ACC/AHA guideline, 79.4% had hypertension, including 17.2% with newly redefined hypertension (130 to 139/80 to 89 mm Hg). Those with newly redefined hypertension had greater risks of major cardiovascular events (hazard ratio: 1.07; 95% confidence interval: 1.04 to 1.10; p < 0.001), ischemic stroke, intracranial hemorrhage, and heart failure admission, compared with nonhypertensive patients (<130/80 mm Hg). Among patients with AF undergoing hypertension treatment, patients with BP ≥130/80 mm Hg or <120/80 mm Hg were at significantly higher risks of major cardiovascular events than patients with BP of 120 to 129/<80 mm Hg.</P> <P><B>Conclusions</B></P> <P>Patients with AF and newly redefined hypertension according to the 2017 ACC/AHA guideline were at higher risk of major cardiovascular events, suggesting that the new BP threshold is beneficial for timely diagnosis and intervention. BP of 120 to 129/<80 mm Hg was the optimal BP treatment target for patients with AF undergoing hypertension treatment.</P> <P><B>Central Illustration</B></P> <P>[DISPLAY OMISSION]</P>

GUM에 의한 위성영상 일사량 불확도 산정

김보영(Boyoung Kim),김창기(Chang Ki Kim),김현구(Hyun-goo Kim),강용혁(Yong-heack Kang) 한국신재생에너지학회 2021 한국신재생에너지학회 학술대회논문집 Vol.2021 No.7

표준기상년(TMY: Typical Meteorological Year)는 건물의 냉난방 부하를 계산하고 태양 및 풍력에너지 및 건물의 냉난방 부하를 계산하는데 필수적인 데이터이다. 한국에너지기술연구원 신재생에너지 데이터센터는 2019년까지 국내에서 30년동안 장기측정한 일사량을 사용하여 표준데이터 생산시스템에 따라 22지점의 TMY 데이터를 생산했다. 또한, 생산한 데이터에 대해, GUM(Guide to the expression of Uncertainty in Measurement)에 의한 불확도와 함께 제공 중이다. 대한민국이 산악지형인 것을 감안하면 22개 지점은 매우 부족하기에 위성영상 일사량을 활용하여 2020년까지 총 100지점의 TMY 데이터를 생산하였다. 현재 위성영상과 모델 기반의 일사량에서 불확도를 평가하는 방법에는 두 가지 이슈가 있다. 첫 번째, 통상적인 A형 불확도 산정이 불가능하다. GUM에서 말하는 A형 불확도는 반복시행에 의한 불확도이다. 즉, 동일한 측정 대상과 측정기기를 활용하여 반복 측정을 시행한 결과, 그에 대한 불확도를 나타낸 것이다. 하지만, 일사량은 시시각각 변하는 대상이며, 동일한 대상이 존재하지 않고 하나의 측정기기를 활용한 반복측정이 불가능하다. 두 번째, 모델식에 대한 감도계수 계산이 힘들다. 위성영상으로부터 일사량을 추정하는 모델은 상당히 복잡한 수학적/기상학정 수식을 가지고 있으며, 기상 조건에 따라 완전히 다른 수식을 적용한다. 따라서, 감도계산이 거의 불가능하다. 본 연구에서는 이와 같은 이슈를 해결하기 위해 모델을 블랙박스로 두고, 측정값과 모델 값의 비교를 통해 모델 자체의 감도계수를 산출하고, 이를 불확도 산정에 활용하였다. 이를 통해 GUM의 가이드를 따르면서도 산업계에서 용인할 수 있는 수준의 불확도를 산정할 수 있었다.

제로에너지 시티 설계에서 위한 3D BIPV 자원지도의 중요성

김보영(Boyoung Kim),윤창열(Chang-yeol Yun),김창기(Chang Ki Kim),강용혁(Yong-heack Kang),김진영(Jin Young Kim),오명찬(Myeongchan Oh),김현구(Hyun-goo Kim) 한국신재생에너지학회 2021 한국신재생에너지학회 학술대회논문집 Vol.2021 No.7

신재생에너지를 이용한 건축물은 제로에너지 건물, 플러스에너지 건물, 제로에너지 타운을 넘어서 제로에너지 시티까지 그 규모를 확장하고 있다. 제로에너지 타운 또는 시티에서 건물 옥상에 설치된 PV 뿐만 아니라 벽면에 부착되는 BIPV는 필수이다. 도심에서 BIPV 사전 경제성 평가를 할 때 가장 중요한 두 가지는 일사량과 음영이다. 건물 음영의 경우 개별 건물에 대한 음영 계산은 개별적으로 3D 모델을 만들어 가능하지만, 제로에너지 시티를 위한 도시 단위의 BIPV 음영 계산을 위해서는 3D BIPV 자원지도가 요구된다. 이미 존재하는 도시지역에 새로운 건물을 설계하거나, 새로운 계획도시를 설계할 때에 3D BIPV 자원지도는 필수적이다. 한국에너지기술연구원 신재생에너지 데이터센터는 대전시 대덕특구와 함께 대전시 건물태양광 자원지도(SEED: Solar Energy Estimator for Daejeon)를 제작하여, 대전시 행망에서 공개서비스 중이다. 대전시의 3D BIPV 자원지도 데이터를 분석해보면, 음영이 없을 때에 대비해서 음영이 있을 때 대전시 전체 건물의 25%가량이 경제성이 없어지는 것을 볼 수 있었다. 또한 기상청에서 공개하는 일사량으로 산정했을 때 대비 음영까지 고려할 경우 발전량이 최대 50%까지 떨어졌다.